A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
A phase 1/2 trial of ABT-301, Tislelizumab, Bevacizumab in colorectal cancer, run by Anbogen Therapeutics, Inc., now recruiting.
Overview
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC is a phase 1/2 interventional study registered as NCT07244705 by Anbogen Therapeutics, Inc., with 66 participants planned, started 2025-11 and due to reach its primary completion in 2028-04. Interventions recorded: ABT-301, Tislelizumab, Bevacizumab (Avastin). Conditions listed: Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus
Shares Tislelizumab, Colorectal cancer.
- TrialStudy of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Shares Tislelizumab, Colorectal cancer.
- TrialA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol
Shares Tislelizumab, Bevacizumab.
- TrialStudy of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Shares Bevacizumab, Colorectal cancer.
- TrialA Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Shares Bevacizumab, Colorectal cancer.
- TrialAK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Shares Bevacizumab, Colorectal cancer.
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3
Shares Bevacizumab, Colorectal cancer.
- TrialA Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta
Shares Bevacizumab, Colorectal cancer.